Antihistamines in the treatment of chronic urticaria

Journal of Investigational Allergology and Clinical Immunology

Volumn 17, Issue SUPPL.2, 2007, Pages 41-52

  Jáuregui Presa, Ignacio ^a   Ferrer, M ^b   Montoro, J ^c   Davila I ^d   Bartra, J ^e   Del Cuvillo, A ^f   Mullol, J ^e   Sastre, J ^g   Valero, A ^e  

^a HOSPITAL DE BASURTO   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c HOSPITAL DE LA PLANA   (Spain)

^d HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f Clinica Dr Lobaton   (Spain)

^g Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

Angioedema; Antidepressants; Autoimmune chronic urticaria; Chronic urticaria; Cysteinyl leukotriene antagonists; H1 antihistamines; H2 antihistamines; Histamine; Inflammation; Physical urticaria; Skin; Skin response to histamine

Indexed keywords

ANTIHISTAMINIC AGENT; AZELASTINE; CETIRIZINE; CYTOCHROME P450 3A4; DESLORATADINE; EBASTINE; EPINASTINE; FEXOFENADINE; HYDROXYZINE; LEVOCETIRIZINE; LORATADINE; MIZOLASTINE; PLACEBO; RUPATADINE; TERFENADINE; ANTIINFLAMMATORY AGENT; HISTAMINE H1 RECEPTOR ANTAGONIST;

ANGIONEUROTIC EDEMA; ANTIINFLAMMATORY ACTIVITY; CHRONIC URTICARIA; CLINICAL TRIAL; DOSE RESPONSE; DROWSINESS; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LIVER METABOLISM; REVIEW; ADOLESCENT; CHILD; CHRONIC DISEASE; FEMALE; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOLOGY; METABOLISM; PATHOLOGY; PREGNANCY; PREGNANCY COMPLICATION; URTICARIA;

ADOLESCENT; ANGIOEDEMA; ANTI-INFLAMMATORY AGENTS; CHILD; CHRONIC DISEASE; FEMALE; HISTAMINE H1 ANTAGONISTS; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; HYPERSENSITIVITY, IMMEDIATE; PREGNANCY; PREGNANCY COMPLICATIONS; URTICARIA;

EID: 38949148691     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Gaig P, Olona M, Muñoz Lejarazu D, Caballero MT, Domínguez FJ, Echechipía S, García Abujeta JL, Gonzalo MA, Lleonart R, Martínez Cócera C, Rodríguez A, Ferrer M. Epidemiology of urticaria in Spain. J Invest Allergol Clin Immunol. 2004; 14:214-220
2. Zuberbier T, Bindslev-Jensen C, Canonica W, Grattan CEH, Greaves MW Henz BM, Kapp A, Kozel MMA, Maurer M, Merk HF, Schäfer T, Simon D, Vena GA, Wedi B. EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy. 2006: 61: 316-320
3. Zuberbier T, Bindslev-Jensen2 C, Canonica W, Grattan CEH, Greaves MW Henz BM, Kapp A, Kozel MMA, Maurer M, Merk HF, Schäfer T, Simon D, Vena GA, Wedi B. EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy. 2006;6:321-331
4. Powell RJ, Du Toit GL, Siddique N, Leech SC, Dixon TA, Clark AT, Mirakian R, Walker SM, Huber PAJ, Nasser SM. BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy. 2007;37:631-650
5. Kaplan AP. Clinical practice: Chronic urticaria and angioedema. N Eng J Med. 2002; 346:175-179
6. Grattan C. Chronic urticaria: General Principles and Management. In: Greaves MW, Kaplan AP, eds. Urticaria and Angioedema. New York: Marcel Dekker. 2004:343-68.
7. Kobza Black A, Greaves MW. Antihistamines in urticaria and angioedema. En: Histamine and H1-antihistamines in allergic disease, 2nd Ed, ed por Simons FER, Marcel Dekker Inc, New York. 2002
8. O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol.1997;136:197-201
9. Grob JJ, Gaudy-Marqueste C. Urticaria and quality of life. Clin Rev Allergy Immunol. 2006; 30:47-51
10. Kaplan AP. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol. 2004; 114:465-474
11. Kozel MMA, Sabroe RA: Chronic urticaria. Aetiology, management and current and future treatment options. Drugs. 2004;64:2515-2536
12. Leznoff A, Sussman GL. Syndrome of idiopathic chronic urticaria and angioedema with thyroid autoimmunity: a study of 90 patients. J Allergy Clin Immunol. 1989;84: 66-71
13. Kaplan AP. Clinical practice: Chronic urticaria and angioedema. N Eng J Med. 2002;346:175-179
14. Hide M, Francis DM, Grattan CE, Hakimi J, Kochan JP, Greaves MW. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. New Engl J Med. 1993;328:1599-604
15. Sabroe RA, Grattan CE, Francis DM, Barr RM, Kobza BA, Greaves MW. The autologous serum skin test: a screening test for autoantibodies in chronic idiopathic urticaria. Br J Dermatol.1999;140:446-452
16. Ferrer M, Kinèt J-P, Kaplan AP. Comparative studies of functional and binding assays for IgG anti-FcERIa (a-subunit) in chronic urticaria. J Allergy Clin Immunol. 1998; 101:672-676
17. Ferrer M, Nakazawa K, Kaplan AP. Complement dependence of histamine release in chronic urticaria. J Allergy Clin Immunol.1999;104:169-172
18. Simons FER, Silver NA, Gu X, Simons KJ. Clinical pharmacology of H1- antihistamines in the skin. J Allergy Clin Immunol. 2002;110:777-783
19. Walsh GM. Anti-inflammatory properties of antihistamines: an update. Clin Exp Allergy Rev. 2005;5:21-25
20. Simons FER. Advances in H1-Antihistamines. N Eng J Med. 2004;351:2203-2217
21. Church MK. Non H1-receptor effects of antihistamines. Clin Exp Allergy. 1999; 29 (Suppl. 3):39-48
22. Leurs R, Church MK, Taglialatela M. H1-antihistamines: Inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy. 2002;32:489-498
23. Du Buske LM. Clinical comparison of histamine H1-receptor antagonist drugs. J Allergy Clin Immunol. 1996;98:S307-318
24. Simons FE, McMillan JL, Simons KJ. A double-blind, single-dose, crossover comparison of cetirizine, terfenadine, loratadine, astemizole, and chlorpheniramine versus placebo: suppressive effects on histamine-induced wheals and flares during 24 hours in normal subjects. J Allergy Clin Immunol. 1990;86:540-547
25. Grant JA, Danielson L,Rihox J-P, De Vos C. A double- blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: supression of histamine-induced wheal and flare response for 24 h in healthy male subjects. Allergy. 1999,54:700-707
26. Rosenzwey P, Caplain H, Chofour S, lliac N, Cabanis MJ, Thebault JJ. Comparative wheal and flare study of mizolastine vs terfenadine,cetirizine, loratadine and placebo in healthy volunteers. Br JClin Pharmacol. 1995;40:459-465
27. Grant AJ, Riethuisen JM, Moulaert B, DeVos C. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann Allergy Asthma Immunol. 2002;88:190-197
28. Janssens MM-L. Astemizole: A non-sedating antihistamine with fast and sustained activity. Clin Rev Allergy. 1993;11:35-63
29. Simons, FER: Histamine and antihistamines. En: Allergy and Allergic Diseases, ed. por Kay AB. Blackwell Science, Ltd. Oxford. 1997.Ch.24:421
30. Simons FER, Silver NA, Gu X, Simons KJ. Skin concentrations of H1-receptor antagonists. J Allergy Clin Immunol. 2001;107:526-530
31. Walsh GM, Annunziato L, Frossard N, Knol K, Levander S, Nicolas JM, Taglialatela M, Tharp MD, Tillement JP, Timmerman H. New insights into the second generation antihistamines. Drugs. 2001, 61:207-236
32. Gillard M, Benedetti MS, Chatelain P, Baltes E. Histamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistamines. Inflamm Res. 2005;54:367-369
33. Asero, R. Chronic unremitting urticaria: is the use of antihistamines above the licensed dose effective? A preliminary study of cetirizine at licensed and above-licensed doses. Clin Exp Dermatol. 2006,32:34-38
34. O'Leary PA, Farber EM. Benadryl in the treatment of urticaria. Proc Staff Meet Mayo Clinic. 1946;20:429-432.
35. Kamide R, Niimura M, Ueda H, Imamura S, Yamamoto S, Yoshida H. Clinical evaluation of ketotifen for chronic urticaria: multicenter double-blind comparative study with clemastine. Ann Allergy. 1989;62:322-325
36. Kalivas J, Breneman D, Tharp M, Bruce S, Bigby M. Urticaria: clinical efficacy of cetirizine in comparison to hydroxyzine and placebo. J Allergy Clin Immunol. 1990;86:1014-1018
37. Guerra L, Vicenzi C, Marchesi E, Tosti A, Pretto E, Bassi R, Ruetta-Fubbian P, De Costanza F. Loratadine and cetirizine in the treatment of chronic urticaria. J Eur Acad Dermatol. 1994;3:148-152
38. Spencer CM, Faulds D, Peters DH. Cetirizine: A reappraisal of its pharmacological properties and therapeutic use in selected allergic disorders. Drugs. 1993;46:1055-1080
39. Raemaekers JG, Uiterwijk MMC, O'Hanlon JF. Effects of loratadine and cetirizine on actual driving and psychometric test performance, and EEG during driving. Eur J Clin Pharmacol. 1992; 42:363-369
40. Kapp A, Demarteau M. Cost effectiveness of levocetirizine in chronic idiopathic urticaria. A pooled analysis of two randomised controlled trials. Clin Drug Invest. 2006;26(1):1-11
41. Juhlin L, Arendt C. Treatment of chronic urticaria with cetirizine dihydrochloride a non-sedating antihistamine. Br J Dermatol. 1988; 119:67-72
42. Finn A, Kaplan AP, Fretwell R, Qu R, Long JA. Double-blind, placebo controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol. 1999; 103:1071-1078.
43. Kalis B. Double-blind multicenter comparative study of ebastine, terfenadine and placebo in the treatment of chronic idiopathic urticaria in adults. Drugs. 1996 52, Suppl. 1:30-34
44. Brostoff J, Fitzharris P, Dunmore C, Theron M, Blondin P. Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria. Allergy. 1996;51:320-325
45. Monroe E, Finn A, Patel P, Guerrero R, Ratner P, Bernstein D, and the Desloratadine Urticaria Study Group. Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: A double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol. 2003;48:535-541
46. Gimenez-Arnau A, Pujol RM, Ianosi S, Kaszuba A, Malbran A, Poop G and the Rupatadine Urticaria Study Group. Rupatadine in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicentre study. Allergy. 2007;62:539-546
47. Alberto N, Tianco EA, Arcilla B, Maano C, Monsanto-Enrile E, Roe F. Efficacy of epinastine in the management of chronic urticaria: a multicenter double-blind placebo controlled trial. Phil J. Internal Medicine. 1997;35:95-98
48. Pons-Guiraud A, Nekam K, Lahovsky J, Costa A, Piacentini A. Emedastine difumarate versus loratadine in chronic idiopathic urticaria: a randomized, double-blind, controlled European multicentre clinical trial. Eur J Dermatol. 2006 16:649-654
49. Abrams RS, Hoffman CP. Use of medication during pregnancy and lactation: general considerations. En: Asthma and Imunological Diseases in Pregnancy and Early Infancy. Schatz M, Zeiger RS, Claman HN, ed. Marcel Dekker Inc, Nueva York. 1998; 141
50. Demoly P, Piette V, Daures JP. Treatment of allergic rhinitis during pregnancy. Drugs. 2003; 63:1813-1820
51. Equipo editorial del Martindale: Antihistamínicos. En Martindale- Guía completa de consulta farmacoterapéutica, dir. por Sweetman SC. Pharma Editores, Barcelona. 2003:531-557
52. Ficha técnica Xazal (Laboratorio UCB Pharma, S.A.)
53. Greene SL, Reed CE, Schroeter AL. Double-blind crossover study comparing doxepin with diphenhydramine for the treatment of chronic urticaria. J Am Acad Dermatol. 1985;12:669-675
54. Bleehen SS, Thomas SE, Greaves MW, Newton J, Kennedy CT, Hindley F, Marks R, Hazell M, Rowell NR, Fairiss GM, Cartwright PH, Glenny HP, Howland K. Cimetidine and chlorpheniramine in the treatment of chronic idiopathic urticaria: a multi-centre randomized double-blind study. Br J Dermatol. 1987;117:81-88
55. Monroe EW, Cohen SH, Kalbfleisch J, Schulz CI. Combined H1 and H2 antihistamine therapy in chronic urticaria. Arch Dermatol. 1981;117:404-407
56. Paul E, Bodeker RH. Treatment of chronic urticaria with terfenadine and ranitidine. A randomized double-blind study in 45 patients. Eur J Clin Pharmacol. 1986;31:277-280
57. Simons FE, Sussman GL, Simons KJ. Effect of the H2-antagonist cimetidine on the pharmacokinetics and pharmacodynamics of the H1-antagonists hydroxyzine and cetirizine in patients with chronic urticaria. J Allergy Clin Immunol. 1995;95:685-693
58. McBayne TO, Siddall OM. Montelukast treatment of urticaria. Ann Pharmacother. 2006;40:939-942
59. Nettis E, Colanardi MC, Paradiso MT, Ferrannini A. Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy. 2004;34:1401-1407
60. Godse KV. Oral montelukast monotherapy is ineffective in chronic idiopathic urticaria: A comparison with oral cetirizine. Indian J Dermatol Venereol Leprol. 2006;72:312-314
61. Bagenstose SE, Levin L, Bernstein JA. The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results. J Allergy Clin Immunol. 2004;113:134-140
62. Reimers A, Pichler C, Helbling A, Pichler WJ, Yawalkar N. Zafirlukast has no beneficial effects in the treatment of chronic urticaria. Clin Exp Allergy. 2002;32:1763-1768
63. Di Lorenzo G, Pacor ML, Mansueto P, Esposito-Pellitteri M, Ditta V, Lo Bianco C, Leto-Barone MS, Di Fede G, Rini GB. Is there a role for antileukotrienes in urticaria? Clin Exp Dermatol. 2006;31:327-334
64. Scow DT, Luttermoser GK, Dickerson KS. Leukotriene inhibitors in the treatment of allergy and asthma Am Fam Physician. 2007;75:65-70
65. Zuberbier T, Aberer W, Burtin B, Rihoux JP, Czarnetzki BM. Efficacy of cetirizine in cholinergic urticaria. Acta Derm Venereol (Stockh). 1995;75:147-149
66. Beattie PE, Dawe RS, Ibbotson SH, Ferguson J. Characteristics and prognosis of idiopathic solar urticaria: a cohort of 87 cases. Arch Dermatol. 2003;139:1149-1154
67. Kyan-Aung U, Hallsworth M, Haskard D, de Vos C, Lee TH. The effects of cetirizine on the adhesion of human eosinophils and neutrophils to cultured human umbilical vein endothelial cells. J Allergy Clin Immunol. 1992;90:270-272
68. Fadel R, David B, Herpin-Richard N, Borgnon A, Rassemont R, Rihoux JP. In vivo effects of cetirizine on cutaneous reactivity and eosinophil migration induced by platelet-activating- factor (PAF-acether) in man. J Allergy Clin Immunol. 1990;86:314-320
69. Juhlin L, Pihl-Lundin I. Effects of antihistamines on cutaneous reactions and influx of eosinophils after local injection of PAF, kallicrein, compound 48/80 and histamine in patients with chronic urticaria and healthy subjects. Acta Derm Venereol. 1992;72:197-200
70. Fadel R, Ramboer I, Chatterjee N, Rihoux JP, Derde MP. Cetirizine inhibits bradykinin-induced cutaneous wheal and flare in atopic and healthy subjects. Allergy. 2000;55:382-385
71. Rédier H, Chanez P, De Vos C, Rifaï N, Clauzel AM, Michel FB, Godard P. Inhibitory effect of cetirizine on the bronchial eosinophil recruitment induced by allergen inhalation challenge in allergic patients with asthma. J Allergy Clin Immunol. 1992;90:215-224
72. Walsh GM: The effects of cetirizine on the function of inflammatory cells involved in the allergic response. Clin Exp Allergy. 1997;27:47-53
73. Fasce L, Ciprandi G, Pronzato C, Cozzani S, Tosca MA, Grimaldi I, Canonica GW. Cetirizine reduces ICAM-1 expression on epithelial cells during nasal minimal persistent inflammation in asymptomatic children with mite-allergic asthma. Int Arch Allergy Immunol. 1996;109:272-276
74. Ciprandi G, Buscaglia S, Pesce GP, Passalacqua G. Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium both in early and latephase reaction after specific allergenic challenge. J Allergy Clin Immunol. 1995; 95:612-621
75. Jinquan T, Reimert CM, Deleuran B, Zachariae C, Simonsen C, Thestrup-Pedersen K. Cetirizine inhibits the in vitro and ex vivo chemotactic responses of T lymphocytes and monocytes. J Allergy Clin Immunol. 1995;95:979-986
76. Sedgwick JB, Busse WW. Inhibitory effect of cetirizine on cytokine-enhanced in vitro eosinophil survival. Ann Allergy Asthma Immunol. 1997;78:581-585
77. Arnold R, Rihoux JP, König W. Cetirizine counter-regulates interleukin-8 release from human epithelial cells (A549). Clin Exp Allergy. 1999;29:1681-1691
78. Albanesi C, Pastore S, Fanales Belasio E, Girolomoni G. Cetirizine and hydrocortisone differentially regulate ICAM-1 expression and chemokine release in cultured human keratinocytes. Clin Exp Allergy. 1998;28:101-109
79. Ciprandi G, Pronzato C, Ricca V, Varese P, Del Giacco GS, Canonica GW. Terfenadine exerts antiallergic activity reducing ICAM-1 expression on nasal epithelial cells in patients with pollen allergy. Clin Exp Allergy. 1995;25:871-878
80. Eda R, Townley RG, Hopp RJ. Effect of terfenadine on human eosinophil and neutrophil chemotactic response and generation of superoxide. Ann Allergy. 1994;73:154-160
81. Abdelaziz MM, Devalia JL, Khair OA, Bayram H, Prior AJ, Davies RJ. Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis. J Allergy Clin Immunol. 1998;101:410-420
82. Eda R, Sugiyama H, Hopp RJ, Bewtra AK, Townley RG. Effect of loratadine on human eosinophil function in vitro. Ann Allergy. 1993;71:373-378
83. Haria M, Fitton A, Peters DH. Loratadine. A reappraisal of its pharmacological properties and therapeutic use in allergic disorders. Drugs. 1994;48:617-637
84. Bayram H, Devalia JL, Khair OA, Abdelaziz MM, Sapsford RJ, Czarlewski W, Campbell AM, Bousquet J, Davies RJ. Effect of loratadine on nitrogen dioxide-induced changes in electrical resistance and release of inflammatory mediators from cultured human bronchial epithelial cells. J Allergy Clin Immunol. 1999;104:93-99
85. Ciprandi G, Pronzato C, Ricca V, Passalacqua G, Danzig M, Canonica GW. Loratadine treatment of rhinitis due to pollen allergy reduces epithelial ICAM-1 expression. Clin Exp Allergy. 1997;27:118-123
86. Ciprandi G, Catrullo A, Cerqueti P, Tosca MA, Canonica GW. Loratadine reduces ICAM-1 expression on conjunctiva after specific challenge in pollen allergic patients. Allergy. 1998;53:545-546
87. Agrawal DK. Anti-inflammatory properties of desloratadine. Clin Exp Allergy. 2004; 34:1342-1348
88. Lieberman PL, Settipane RA. Azelastine nasal spray: a review of pharmacology and clinical efficacy in allergic and nonallergic rhinitis. Allergy Asthma Proc. 2003;24:95-105
89. Goldhill J, Pichat P, Roome N, Angel I, Arbilla S. Effect of mizolastine on visceral sensory afferent sensitivity and inflammation during experimental colitis. Arzneim-Forsch. 1998;48:179-184
90. Sudo K, Nagai K, Yamada N. Inhibitory effect of mizolastine on 5-lypoxygenase. Jpn Pharmacol Ther. 1998; 26 (Suppl.):s711-713
91. Xia Q, Yang S, Zhang SQ, Chen B, Wang DB, Zhu QX, Wang Y, Yan KL, He PP, Zhang XJ. The effect of mizolastine on expression of vascular endothelial cell growth factor, tumour necrosis factor-alpha and keratinocyte-derived chemokine in murine mast cells, compared with dexamethasone and loratadine. Clin Exp Dermatol. 2005;30:165-170
92. Queralt M, Brazis P, Merlos M, de Mora F, Puigdemont A. In vitro inhibitory effect of rupatadine on histamine and TNF-alpha release from dispersed canine skin mast cells and the human mast cell line HMC-1. Inflamm Res. 2000;49:355-360
93. Belaich S, Bruttmann G, DeGreef H, Lachapelle JM, Paul E, Pedrali P, Tennstedt D. Comparative effects of loratadine and terfenadine in the treatment of chronic idiopathic urticaria. Ann Allergy. 1990;64:191-194
94. Monroe EW, Bernstein DI, Fox RW, Grabiec SV, Honsinger RW, Kalivas JT, Katz HI, Cuss F, Danzig MR, Garvin PR. Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria. Arzneimittelforschung. 1992;42:1119-1121
95. Ring J; Gauger A, Hein R. Clinical Efficacy of Desloratadine in Chronic Urticaria. Clin Drug Invest. 2002; 22 (Suppl 2):33-41